Literature DB >> 23485519

Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention.

Wan-Hsin Wen1, Mei-Hwei Chang, Lu-Lu Zhao, Yen-Hsuan Ni, Hong-Yuan Hsu, Jia-Feng Wu, Pei-Jer Chen, Ding-Shinn Chen, Huey-Ling Chen.   

Abstract

BACKGROUND & AIMS: Immunoprophylaxis reduces but does not completely eradicate hepatitis B virus (HBV) transmission. This prospective study aims at assessing the rate and risk factors of maternally transmitted HBV infection.
METHODS: We enrolled 303 mother-infant pairs with positive maternal hepatitis B surface antigen (HBsAg) under current immunization program. Maternal viral load was determined by a real-time PCR-based assay. The children were tested for HBsAg at 4-8 months and/or 1-3 years of age. Rates of HBV infection were estimated using a multivariate logistic regression model.
RESULTS: HBeAg-positive mothers (81/303, 26.7%) had higher viral loads than HBeAg-negative mothers (7.4 ± 1.9 vs. 2.7 ± 1.4 log10 copies/ml, p<0.0001). Ten children, born to HBeAg-positive mothers with high viral load (median, 8.4; range, 6.5-9.5 log₁₀ copies/ml), were chronically infected. After adjustment for maternal age, birth type, factors related to maternal-fetal hemorrhage, gestational age, infant gender, birth weight, timeliness of vaccination, and feeding practice, maternal viral load was significantly associated with risk of infection (adjusted odds ratio for each log₁₀ copy/ml increase, 3.49; 95% confidence interval (CI), 1.63-7.48; p=0.001). The predictive rates of infection at maternal viral load levels of 7, 8, and 9 log₁₀ copies/ml were 6.6% (95% CI, 0.5-12.6%; p=0.033), 14.6% (95% CI, 5.6-23.6%; p=0.001), and 27.7% (95% CI, 13.1-42.4%; p<0.001), respectively.
CONCLUSIONS: Additional strategies to further reduce transmission should be considered in mothers with a viral load above 7-8 log₁₀ copies/ml.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23485519     DOI: 10.1016/j.jhep.2013.02.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  68 in total

Review 1.  Crossing the scale from within-host infection dynamics to between-host transmission fitness: a discussion of current assumptions and knowledge.

Authors:  Andreas Handel; Pejman Rohani
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-08-19       Impact factor: 6.237

Review 2.  Molecular biology of hepatitis B virus infection.

Authors:  Christoph Seeger; William S Mason
Journal:  Virology       Date:  2015-03-07       Impact factor: 3.616

Review 3.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

4.  Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.

Authors:  Gonzague Jourdain; Nicole Ngo-Giang-Huong; Linda Harrison; Luc Decker; Woottichai Khamduang; Camlin Tierney; Nicolas Salvadori; Tim R Cressey; Wasna Sirirungsi; Jullapong Achalapong; Prapap Yuthavisuthi; Prateep Kanjanavikai; Orada P Na Ayudhaya; Thitiporn Siriwachirachai; Sinart Prommas; Prapan Sabsanong; Aram Limtrakul; Supang Varadisai; Chaiwat Putiyanun; Pornnapa Suriyachai; Prateung Liampongsabuddhi; Suraphan Sangsawang; Wanmanee Matanasarawut; Sudanee Buranabanjasatean; Pichit Puernngooluerm; Chureeratana Bowonwatanuwong; Thanyawee Puthanakit; Virat Klinbuayaem; Satawat Thongsawat; Sombat Thanprasertsuk; George K Siberry; Diane H Watts; Nahida Chakhtoura; Trudy V Murphy; Noele P Nelson; Raymond T Chung; Stanislas Pol; Nantasak Chotivanich
Journal:  N Engl J Med       Date:  2018-03-08       Impact factor: 91.245

5.  Prevention of mother-to-child transmission: the key of hepatitis B virus elimination.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2018-04-04       Impact factor: 6.047

6.  Predictors of Infant Hepatitis B Immunization in Cameroon: Data to Inform Implementation of a Hepatitis B Birth Dose.

Authors:  Jodie Dionne-Odom; Andrew O Westfall; Divine Nzuobontane; Michael J Vinikoor; Gregory Halle-Ekane; Thomas Welty; Alan T N Tita
Journal:  Pediatr Infect Dis J       Date:  2018-01       Impact factor: 2.129

Review 7.  Liver diseases in pregnancy: diseases not unique to pregnancy.

Authors:  Ashraf A Almashhrawi; Khulood T Ahmed; Rubayat N Rahman; Ghassan M Hammoud; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.

Authors:  Tim R Cressey; Linda Harrison; Jullapong Achalapong; Prateep Kanjanavikai; Orada Patamasingh Na Ayudhaya; Prateung Liampongsabuddhi; Thitiporn Siriwachirachai; Chaiwat Putiyanun; Pornnapa Suriyachai; Camlin Tierney; Nicolas Salvadori; Dujrudee Chinwong; Luc Decker; Yardpiroon Tawon; Trudy V Murphy; Nicole Ngo-Giang-Huong; George K Siberry; Gonzague Jourdain
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

9.  Presence of Precore (C)/C Promoter Mutants in Peripheral Blood Mononuclear Cells of Chronic Hepatitis B (CHB) Carriers During Pregnancy Does Not Correlate with Increased Risk of Liver Disease in 4 Years of Follow-Up.

Authors:  Shivali S Joshi; Shan Gao; Eliana Castillo; Carla S Coffin
Journal:  Dig Dis Sci       Date:  2019-08-02       Impact factor: 3.199

Review 10.  Hepatitis B virus: where do we stand and what is the next step for eradication?

Authors:  Haruki Komatsu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.